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Two Coiled-Coil Domains of Chlamydia trachomatis IncA
Affect Membrane Fusion Events during Infection
Erik Ronzone, Fabienne Paumet*
Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America
Abstract
Chlamydia trachomatis replicates in a parasitophorous membrane-bound compartment called an inclusion. The inclusions
corrupt host vesicle trafficking networks to avoid the degradative endolysosomal pathway but promote fusion with each
other in order to sustain higher bacterial loads in a process known as homotypic fusion. The Chlamydia protein IncA
(Inclusion protein A) appears to play central roles in both these processes as it participates to homotypic fusion and inhibits
endocytic SNARE-mediated membrane fusion. How IncA selectively inhibits or activates membrane fusion remains poorly
understood. In this study, we analyzed the spatial and molecular determinants of IncA’s fusogenic and inhibitory functions.
Using a cell-free membrane fusion assay, we found that inhibition of SNARE-mediated fusion requires IncA to be on the
same membrane as the endocytic SNARE proteins. IncA displays two coiled-coil domains showing high homology with
SNARE proteins. Domain swap and deletion experiments revealed that although both these domains are capable of
independently inhibiting SNARE-mediated fusion, these two coiled-coil domains cooperate in mediating IncA multi-
merization and homotypic membrane interaction. Our results support the hypothesis that Chlamydia employs SNARE-like
virulence factors that positively and negatively affect membrane fusion and promote infection.
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Introduction
Chlamydia remains a significant socioeconomic and medical
burden despite decades of steadfast research. Chlamydia trachomatis
is the causative agent of chlamydiosis in humans. Infection is
associated with pelvic inflammatory disease in women and severe
tissue scarring and infertility in both men and women. Inoculation
of the conjunctiva with C. trachomatis leads to inflammation and
trachoma–the leading cause of infectious blindness in the world
[1]. In 2011, over 1.4 million cases of Chlamydia infection were
reported, making Chlamydia one of the most frequently reported
sexually transmitted diseases in the United States (US Centers for
Disease Control).
Chlamydiae exhibit a biphasic lifecycle, existing as metabolically
inert but infectious elementary bodies (EBs) outside the cell and
actively dividing reticulate bodies (RBs) inside. EBs direct their
own internalization into host cells–typically mucosal epithelial
cells–and modify the nascent phagosome into a replicative niche
called an inclusion [2]. Between 10 and 12 hours post infection
(hpi), two or more inclusions in the same cell begin to fuse into a
single large inclusion in a process known as homotypic fusion [3].
Strains of Chlamydia that do not fuse their inclusions are unable to
generate high bacterial loads and are less pathogenic than fusion-
competent strains [4,5]. Unlike phagosomes of non-pathogenic
bacteria that ultimately traffic to lysosomes, the inclusion interacts
with early (and possibly late) endocytic compartments, but avoids
lysosomes altogether [6–10]. Early endocytic markers like trans-
ferrin receptor cluster around the inclusion ,4 hours post
infection (hpi), but lysosomal markers LAMP-1 and LAMP-2 are
not detectable as late as 20 hpi [9,10]. Importantly, the failure of
these markers to appear on the inclusion is not due to a global
breakdown of the endocytic process as yeast particles are still
trafficked successfully to lysosomes in Chlamydia-infected cells [11].
These observations suggest that the avoidance of lysosomes is an
active process and is intrinsic to the inclusion.
Canonical phagosomes successively fuse with early and late
endosomes before fusing with lysosomes in a tightly regulated
manner [12]. At the heart of this process are SNARE (soluble N-
ethylmaleimide sensitive factor attachment receptor) proteins.
SNAREs reside on the cytosol-exposed surfaces of membranous
organelles and catalyze the specific fusion of intracellular
compartments [13–15]. The SNAREs controlling late endo-
some/lysosome fusion are Syntaxin7 (Stx7), Stx8, Vti1b, and
VAMP8 [16–18]. Stx7, Stx8, and Vti1b form a t-SNARE (target-
SNARE) complex on the target membrane. This complex, in turn,
binds the cognate vesicle-localized SNARE (v-SNARE) VAMP8 in
trans to form a four-helix coiled-coil bundle that fuses late
endosomes and lysosomes. The centrality of SNARE proteins to
trafficking makes them ideal targets for pathogens attempting to
establish residence in the cell [19].
Previously, we have demonstrated that IncA, a Chlamydia
protein that resides on the inclusion membrane, inhibits the
fusion of liposomes carrying Stx7, Stx8, Vti1b, and VAMP8 [20].
This inhibition is specific because the rate of fusion of liposomes
reconstituted with the exocytic SNARE complex Stx4, SNAP23,
and VAMP8 is not affected [19,20]. Interestingly, IncA has also
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been implicated in homotypic fusion of the inclusions [3]. How
IncA performs these two functions is unknown.
IncA contains a transmembrane domain (TMD) flanked by two
cytosol-exposed regions on either side [21]. We will refer to these
domains as the N-terminal tail and the C-terminal cytoplasmic
domain. The C-terminal cytoplasmic domain itself contains two
putative coiled-coil domains (CCDs) that show strong homology to
eukaryotic SNARE motifs [20]. Interestingly, mutations in IncA’s
CCDs ablated binding to VAMP8 in vivo [22]. However, the role
of the N-terminal tail, as well as the function of each individual
SNARE-like motif in the C-terminal cytoplasmic domain, remains
unclear.
In this report, IncA’s proper topological organization to exert its
function was first determined. Using this topology, we next
determined the role of each protein domain (i) for IncA to inhibit
SNARE-mediated membrane fusion and (ii) for IncA to interact
with itself and induce homotypic fusion. We found that optimal
SNARE-mediated membrane fusion inhibition requires that IncA
be on the same membrane as the SNARE proteins. A series of
mutations and truncations revealed a previously unknown role for
the C-terminal coiled-coil domain (CCD) of IncA as an
independent inhibitor of membrane fusion. However, in vivo
characterization of these IncA mutants uncovered that coopera-
tion between the two CCDs is necessary to mediate homotypic
fusion.
Altogether, our data identify two functional SNARE-like
domains (SLDs) in IncA. We show for the first time that the N-
terminal SNARE-like domain SLD1 and the C-terminal SNARE-
like domain SLD2 can work independently to inhibit membrane
fusion. However, they are both required to promote homotypic
fusion. Our data provide new insight regarding how C. trachomatis
interferes with membrane fusion and support the hypothesis that
intracellular pathogens utilize SNARE-like proteins to promote
infection.
Experimental Procedures
DNA Constructs
A list of primers and sequences are summarized in Table S1.
The plasmid encoding 6xHis-D34IncA (FD231) was generated by
PCR using primers FO136 and FO137 and plasmid FD201
(expression vector for IncA-6xHis wildtype) as template. The
resulting PCR product was digested with EcoRI and BamHI (New
England Biolabs, NEB) and ligated into pET28a (Novagen).
The expression plasmid encoding 6xHis-DTMD-IncA (FD199)
and 6xHis-TfR-IncA (FD204) were a kind gift from Dr. A. Subtil.
To create the expression plasmid for GST (glutathione S-
transferase)-TfR-IncA, the coding sequence for TfR-IncA was
cleaved from plasmid FD204 with NdeI and EcoRI and ligated into
pGEX vector [23]. Site-directed mutagenesis of truncated (IncA1–
141) and full-length IncA was accomplished using the QuickChange
system (Stratagene). Mutagenic primers FO401 and FO402 were
used to introduce the mutations I106D/T127D/V134D into
plasmids FD229 (expression plasmid for 6xHis-IncA1–141) and
FD201 to generate plasmids FD465 (encoding 6xHis-Asp-IncA1–141)
and FD464 (encoding Asp-IncA-6xHis), respectively. Mutagenic
primers FO414 and FO416 were used to introduce mutations
F108A/F117A/F124A/F138A into FD465 to generate FD475
(encoding 6xHis-Phe/Asp-IncA-141). Primers FO414 and FO415
were used to introduce mutations F108A/F117A/F124A/F138A/
F145A into FD464 to generate FD472 (encoding Phe/Asp-IncA-
6xHis). GST was fused to the C-terminal cytoplasmic domains of
IncA1–141, Phe/Asp-IncA1–141, and Phe/Asp-IncA by first ampli-
fying the gene segment encoding the cytoplasmic domain using
primers FO399 and FO400 (for GST-IncA1–141 and GST-Phe/
Asp-IncA1–141) and FO399 and FO137 for GST-Phe/Asp-IncA
and ligating into pGEX vector.
pDsRed-IncA plasmids were constructed by amplifying the open
reading frames of FD201, FD229, FD231, FD472, and FD475
using primers FO124 and FO125 (for wildtype and Phe/Asp-IncA),
FO124 and FO162 (for IncA1–141 and Phe/Asp-IncA1–141), or
FO441 and FO125 for D34-IncA and ligating into the pDs-Red-
monomer-C1 vector (kindly provided by Dr. P. Antinozzi). All
constructs were verified by sequencing at the Nucleic Acids Facility
at Thomas Jefferson University.
Protein Induction and Purification
BL21(DE3) carrying the plasmids of interest were grown in
Luria-Bertani (LB) liquid medium supplemented with appropriate
antibiotic (50 mg/mL kanamycin and/or 100 mg/mL ampicillin)
at 37uC to mid-log phase before adding isopropyl-b-D-1-
thiogalactopyranoside to a final concentration of 0.2 mM.
Incubation temperature was then lowered to 16uC and the culture
was incubated overnight. Induced BL21(DE3) were collected by
centrifugation and the pellets stored at 220uC.
For protein purification, bacterial pellets were resuspended in
Breaking Buffer (200 mM KCl, 25 mM HEPES, 10% glycerol,
4% Triton X-100, pH7.4) supplemented with 5 mM b-mercap-
toethanol and protease inhibitors. Bacteria were lysed by passage
through an EmulsiFlex-C3 homogenizer (Avestin). Cellular debris
was pelleted by ultracentrifugation. To purify 6xHis-tagged
proteins, supernatants containing tagged proteins were incubated
with nickel nitriloacetic acid (Ni-NTA) agarose beads (Qiagen) for
1 h at 4uC. Beads were washed with 30–100 mM imidazole in
Buffer A (200 mM KCl, 25 mM HEPES, 10% glycerol, 0.8% n-
octyl-b-D-glucopyranoside, pH7.4 with 5 mM b-mercaptoetha-
nol). Proteins were eluted with Buffer A containing 500 mM
imidazole. For GST-tagged protein purification, supernatants
containing the GST-proteins were incubated with glutathione
agarose beads (Sigma Aldrich) for 1 h at 4uC. Beads were collected
on a Poly-Prep column and washed with three column volumes
(,30 mLs) of Buffer A. Proteins were cleaved from the GST tag
and eluted from the agarose matrix using thrombin. Briefly,
thrombin (Fisher Scientific) was diluted to 0.05 U/ul in Buffer A
and incubated with the agarose matrix for 2 h at room
temperature. Thrombin reactions were stopped by adding 4-(2-
aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF,
Fisher Scientific).
Proteoliposome Reconstitution and Liposome Fusion
Assay
Liposomes were prepared as described [24,25]. The lipid
components in the acceptor liposomes are 85% palmitoyl-oleoyl-
phosphatidylcholine (POPC) and 15% 1,2-dioleoyl-phosphatidyl-
serine (DOPS), corresponding to 15 mM total lipids in CHCl3.
The donor liposomes contain 82% POPC, 15% DOPS, 1.5% 7-
nitrobenz-2-oxa-1,3-diazole-dipalmitoyl phosphatidyl ethanol-
amine (NBD-DPPE), 1.5% Rhodamine-DPPE, corresponding to
3 mM total lipids in CHCl3. All lipids were obtained from Avanti
Polar Lipids, Inc. Briefly, recombinant proteins were mixed with
lipids in the presence of detergent for 30 min at room
temperature. Dialysis buffer (200 mM KCl, 25 mM HEPES,
10% glycerol, 1 mM dithiothreitol, pH7.4) was added to the
mixture to form liposomes, and detergent was removed by
overnight dialysis at 4uC. Liposomes were further purified by
density gradient centrifugation.
The liposome fusion assay was performed essentially as
described [24,25]. 45 mL of t-SNARE liposomes and 5 mL of v-
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SNARE liposomes were mixed and incubated at 37uC for 2 h.
Nitrobenzoxadiazole (NBD) fluorescence was measured every
2 min. Maximum fluorescence values resulting from complete
dequenching of NBD were obtained by adding 10 mL of n-
dodecyl-b-D-maltoside detergent (stock concentration 2.5% w/v)
to each reaction after the initial 2 h incubation. The percent
fluorescence was calculated as follows:
%Fluorescence(t)~
f (t){fmin
fmax{fmin
|100
where f(t) is the fluorescence at time t, fmin is the minimum
fluorescence value observed for that reaction, and fmax is the
maximum fluorescence value.
The topology experiment in Figure 1 followed the same basic
protocol above, except that 10 mL of the third liposome
population, empty or containing wildtype IncA, was added to
each reaction. The percent inhibition by IncA in each configu-
ration was calculated using the equation:
%Inhibition~
%Fluorescencewithout IncA{%Fluorescencewith IncA
%Fluorescencewithout IncA
|100
Circular Dichroism Spectroscopy
DTMD-proteins corresponding to the C-terminal cytoplasmic
domains of wildtype IncA, IncA1–141, Phe/Asp-IncA1–141, and
Phe/Asp-IncA were GST purified as described above. They were
further purified by size-exclusion chromatography using a HiLoad
16/60 pg200 column (GE Lifesciences) equilibrated in 200 mM
NaCl, 20 mM Tris, 10% glycerol, pH7.4 supplemented with
5 mM b-mercaptoethanol. Protein-containing fractions were
pooled and exchanged into CD Buffer (200 mM NaF, 20 mM
Tris, 10% glycerol, pH7.4 with 1 mM dithiothreitol). Protein
concentrations were determined by measuring the optical density
at 280 nm. Wavelength scans were collected in a 1 mm pathlength
quartz cuvette (Starna) using a JASCO J-810 spectropolarimeter
equipped with a Peltier temperature control device. Measurements
were taken at 20uC.
Co-elution Assay
BL21(DE3) were co-transformed with plasmid FD439 and
either FD201, FD231, FD229, FD475, or FD472. Bacteria were
induced overnight as described above. Equal volumes of overnight
culture were harvested by centrifugation and resuspended in
Buffer A supplemented with 5 mM b-mercaptoethanol and 1 mM
AEBSF. Bacteria were sonicated in three 20-second pulses with
1 min recoveries on ice. Cell debris was separated by centrifuga-
tion, and the supernatants were incubated over glutathione
agarose beads at 4uC for 1 h. Beads were washed twice with
Buffer A supplemented with 5 mM b-mercaptoethanol. Bound
proteins were eluted by resuspending beads in 2% SDS protein
loading buffer before boiling. Equal volumes of each co-elution
were run subjected to SDS-PAGE. GST and GST fusion proteins
were visualized by Coommassie Blue staining. Co-eluted proteins
were visualized by western blot using rabbit a-6xHis primary
antibody (Santa Cruz) and donkey a-rabbit horse raddish
peroxidase-conjugated secondary antibody (GE Healthcare).
Protein bands were detected using enhanced chemiluminescence
(ECL) reagents (GE Healthcare). Blots were visualized using a
FluorChem M imager (ProteinSimple). As a loading control,
10 mL of supernatant lysate were run on SDS-PAGE and blotted,
as above, for 6xHis-tagged proteins.
Immunofluorescent Microscopy
HeLa cells were cultured in DMEM containing 10% fetal
bovine serum, L-glutamine and 10 mg/mL gentamicin. HeLa cells
were seeded in 24-well plates at 2.46104 cells/well and incubated
overnight. Cells were transfected using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol. 24 h after
transfection, cells were infected with C. trachomatis, LGV str. L2
(kindly provided by Dr. T. Hackstadt, NIAID). 24 hpi, cells were
fixed in 2% formaldehyde for 30 min at 4uC. DNA was stained
with 1 mg/ml Hoechst. Images were acquired using a Nikon
Eclipse Ti inverted fluorescence microscope equipped with
appropriate filters, 606 oil immersion objective, and NIS
Elements software (Nikon). Images were analyzed using ImageJ
(NIH).
Statistical Analysis
Statistics were calculated using Student’s two-tailed t-test.
Significance is defined as p#0.05.
Results
Inhibition of SNARE-Mediated Liposome Fusion by IncA
is Topologically Restricted
Efficient SNARE-mediated fusion requires that a t-SNARE
complex form on one bilayer before interacting with a cognate v-
SNARE on an opposing bilayer. This topological restriction
ensures aberrant fusion events are avoided and the integrity of
organelles is maintained [26]. We theorized that IncA would be
similarly topologically restricted. As a result, the inclusion would
be protected and fusion with destructive compartments would be
prevented. To test this hypothesis, we mimicked different IncA
configurations in an in vitro fusion assay. We first generated three
liposome populations: one carrying the late endocytic t-SNAREs
Syntaxin7 (Stx7), Stx8, and Vti1b, one carrying the v-SNARE
VAMP8, and a third empty liposome population (Figure 1B, 1C,
1D). Next, we inserted IncA either on the t-SNARE liposome
(Fig. 1C), or on the v-SNARE liposome (Fig. 1D), or on the third
liposome (Fig. 1B) and calculated the percent inhibition generated
by IncA in each topological configuration. The v-SNARE
liposomes contain two fluorescent lipids (Rhodamine-phosphatidyl
ethanolamine (PE) and NBD-PE), which undergo resonance
energy transfer (FRET) when in close proximity such that NBD
fluorescence is quenched [25]. Upon membrane fusion with
unlabeled t-SNARE liposomes, the fluorophores are diluted and
increased NBD fluorescence at 538 nm is measured, providing a
quantitative readout of fusion. The third liposome population is
also constituted with non-labeled lipids.
Using this setup, we found that IncA requires insertion in the
same membrane as the endocytic SNAREs in order to exert its
inhibitory function (Fig. 1A). Placing IncA on the third liposome
population fails to significantly affect late endocytic SNARE-
driven fusion (Figure 1B), and only 1.7% inhibition is observed.
SDS-PAGE analysis of liposomes shows incorporation of proteins
(Fig. 1B, Coomassie gel). In contrast, the inhibitory capacity of
IncA is significantly higher when IncA is reconstituted with either
the t- or v-SNARE complex (,15% and ,42% inhibition,
respectively). As previously demonstrated, the inhibition is less
pronounced when IncA is reconstituted on the t-SNARE liposome
due to the restricted amount of IncA inserted into these liposomes
[20]. Since IncA has been shown to bind VAMP8 in vitro and
in vivo, it is likely that the close proximity of IncA to VAMP8 when
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both are on the same membrane contributes to the robust
inhibition [22]. These data suggest that the topological arrange-
ment of IncA relative to SNARE complexes constitutes a
significant factor in its ability to inhibit SNARE complexes.
The Inhibitory Ability of IncA Is Isolated To The C-
terminal Cytoplasmic Domain
Since IncA has an optimal inhibitory function when inserted
with the v-SNARE (Figure 1D), we next tested the function of each
IncA domain (Fig. 2A) using this configuration. Previously, we
have demonstrated a role for SLD1 in the inhibition of SNARE-
mediated liposome fusion [20]. The observation that an IncA
mutant lacking SLD2 was still capable of inhibiting fusion
suggested that SLD1 was sufficient to confer inhibitory ability.
Here, we determined whether SLD1 requires the input of other
domains–namely, the N-terminal tail (amino acids 1–34) and/or
the transmembrane domain (TMD)–to successfully inhibit mem-
brane fusion. To test for the importance of this domain, we
generated an IncA mutant lacking the N-terminal tail region (D34-
IncA).
When D34-IncA is co-reconstituted with VAMP8, fusion is still
significantly inhibited (Fig. 2B). Furthermore, we found that
increasing the ratio of D34-IncA to VAMP8 on liposomes
consistently leads to more pronounced inhibition. At a 1:2 molar
ratio, normalized NBD fluorescence decreases from ,17% for
liposomes not containing D34-IncA to ,14% (an 18% overall
decrease) (Fig. 2B). At a 1:1 ratio, normalized fluorescence
decreases by about 35%, and for a 2:1 ratio, there is a 53%
decrease in signal. The correlation between increasing ratios of
D34-IncA:VAMP8 and lower levels of NBD fluorescence suggests
Figure 1. Inhibition of SNARE-mediated fusion by IncA is topologically restricted. The inhibitory capacity of IncA was assessed in three
topological configurations–on the t-SNARE liposome, v-SNARE liposome, or a third liposome. 45 mL of t-SNARE liposome reconstituted with Stx7,
Stx8, Vti1b were mixed with 5 mL of v-SNARE liposome reconstituted with VAMP8 and 10 mL of third liposome and NBD fluorescence was measured
every two minutes for 2 hrs at 37uC. 10 mL of n-Dodecyl-b-D-maltoside (2.5% w/v stock concentration) was added at the end of the 2 hrs and data
were normalized to the 100% fluorescence value as described [24]. For each condition, IncA was reconstituted into just one liposome population, and
its inhibition tested. (A) The average percent inhibition of IncA in each indicated liposome is presented. Error bars represent one standard deviation
from three independent experiments. IncA inhibits SNARE-mediated liposome fusion significantly better when co-reconstituted with SNARE proteins.
(B) IncA fails to inhibit when reconstituted singly on the third liposome population. Black circles represent fusion in the absence of IncA, red squares
in the presence of IncA. Inset illustrates position of IncA (red bar) relative to SNARE proteins (black bars). SDS-PAGE analysis reveals incorporation of
proteins into liposomes. The positions of each protein and liposome population are denoted. The fusion graph is representative of three independent
experiments. (C) IncA inhibits fusion when reconstituted with the t-SNAREs. The design of the experiment was identical to (B), except that IncA was
reconstituted with the late endocytic t-SNARE complex on the t-SNARE liposome. The fusion graph is representative of three independent
experiments. (D) IncA inhibits fusion when reconstituted with the v-SNARE. The design of the experiment was identical to (B), except that IncA was
reconstituted with the late endocytic SNARE VAMP8 on the v-SNARE liposome. The fusion graph is representative of three independent experiments.
doi:10.1371/journal.pone.0069769.g001
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that the observed inhibition is specific for D34-IncA and is
consistent with previous observations for wildtype IncA [20]. In
all, these data show that the N-terminal tail region is dispensable
for IncA’s inhibitory function.
We then investigated whether the TMD of IncA contributes to
inhibition. Interactions between cognate SNAREs are stabilized
by the participation of their TMDs [27,28]. We reasoned that the
bi-lobed TMD of IncA may promote inhibition of membrane
fusion by directing IncA to sites of SNARE complex formation or,
more generally, to areas of membrane occupied by SNARE
proteins via hydrophobic interactions. To address this possibility,
we purified a mutant of IncA in which the N-terminal tail region
and TMD were replaced by a non-SNARE TMD, namely that of
the transferrin receptor. DNA sequencing of the transferrin
receptor-IncA chimera reveals a TMD of ,24 amino acids
compared to ,40 amino acids for IncA, making the TMD
considerably smaller (data not shown).
Similar to D34-IncA, TfR-IncA inhibits lipid mixing in a dose-
dependent fashion (Fig. 2C). At a 1:4 ratio of TfR-IncA:VAMP8,
NBD fluorescence decreases by ,25%, and for a 1:2 ratio,
fluorescence decreases by about 50%. Taken together, these
results suggest that neither the N-terminal tail region nor the
hydrophobic TMD of IncA is necessary for the inhibition of late
endocytic SNARE-mediated liposome fusion. This confirms that
the inhibitory ability of IncA is confined to the C-terminal
cytoplasmic domain containing the two putative coiled-coil
domains.
SLD2 Inhibits Late Endocytic SNARE-Mediated Fusion
Independently of SLD1
The C-terminal cytoplasmic domain of IncA encodes two
SNARE-like domains, SLD1 and SLD2 [20]. We hypothesized
that SLD2 was also able to inhibit liposome fusion based on
several observations. First, in addition to showing a high
propensity towards coiled-coil formation, SLD2 contains a
glutamine residue that aligns with other glutamine residues
conserved in the 0-layer of a variety of SNARE proteins including
Syntaxins 6, 7, 8, and 16 [22]. Secondly, mutating this residue to
an arginine diminished IncA binding to VAMP8 in an in vivo
pulldown assay [22].
To determine whether SLD2 was independently capable of
inhibiting fusion, we first introduced point mutations into SLD1 to
abolish its functionality. We chose to inactivate the function of
SLD1 using point mutations instead of truncations in order to keep
the overall organization of the protein intact. In particular, this
strategy allows the location of SLD2 relative to the transmem-
brane domain to be conserved.
The primary sequence of SLD1 reveals a putative 3–4 heptad
repeat of the form a-b-c-d-e-f-g where the ‘‘a’’ and ‘‘d’’ residues are
hydrophobic. We mutated the amino acids isoleucine, valine, and
threonine located in the ‘‘d’’ positions in SLD1 to aspartates
because b-branched amino acids in this position have been shown
to stabilize coiled-coil formation [29,30]. Furthermore, we
mutated the phenylalanines in SLD1 to alanines. Phenylalanines
are prevalent in SNARE motifs and have been shown to stabilize
coiled-coil membrane proteins [31]. Mutations are depicted as red
coils in Figure 3 (B and C).
Truncated IncA mutants containing wildtype SLD1 (IncA1–141)
inhibit fusion approximately 25% at IncA:VAMP8 ratios of 1:2
(Fig. 3A), consistent with our previous results [20]. When the
Figure 2. The N-terminal tail region and transmembrane
domain of IncA are dispensible for the inhibitory function of
IncA. (A) Schematic of full-length wildtype IncA. The N-terminal tail
encompasses the first 34 amino acids. The transmembrane domain is
depicted by the black area (amino acids 35–82). SNARE-like domain1
(SLD1) is located between amino-acids 107 and 145; SLD2 between
amino-acids 210 and 273. (B) 45 mL of t-SNARE liposome reconstituted
with Stx7, Stx8, Vti1b were mixed with 5 mL of v-SNARE liposome
reconstituted with VAMP8 and an increasing concentration of IncA.
NBD fluorescence was measured every 2 min for 2 hrs at 37uC. 10 mL of
n-Dodecyl-b-D-maltoside (2.5% w/v stock concentration) was added to
the reaction and data were normalized to the 100% fluorescence value
as described [24]. Protein gel lanes show co-reconstitution of D34-IncA
with VAMP8 on v-SNARE liposomes. Values next to protein gel lanes
refer to the ratio of IncA mutant to VAMP8 for that particular fusion
curve. (C) Fusions were performed as in (B) except that the N-terminal
tail region and TMD of IncA were replaced with the TMD of the
transferrin receptor (TfR) before reconstituting increasing concentration
of this chimeric protein with VAMP8. For (B) and (C), black circles
represent fusion in the absence of IncA mutant and gray squares
represent fusion in the presence of increasing concentrations of IncA
mutant relative to VAMP8. Results are representative of at least four
independent experiments.
doi:10.1371/journal.pone.0069769.g002
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Figure 3. SLD2 inhibits late endocytic SNARE-mediated fusion independently of SLD1. (A) SLD1 is sufficient for SNARE inhibition.
Increasing concentrations of IncA1–141 were reconstituted in v-SNARE liposomes with VAMP8 and mixed with t-SNARE liposomes in which Stx7, Stx8,
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above mutations were introduced into this region of IncA (Phe/
Asp-IncA1–141), this mutant became incapable of inhibiting late
endocytic SNARE-mediated fusion even at IncA:VAMP8 ratios of
2:1, demonstrating that this series of mutations was effective to
completely inactivate SLD1 (Fig. 3B). When these mutations were
introduced into the full-length IncA protein (Phe/Asp-IncA) in
which SLD2 is still active, robust inhibition is restored (Fig. 3C).
This suggests that SLD2 has an inhibitory function that can act
independently of SLD1.
The considerable loss in activity of IncA could be explained by a
concomitant loss of structure in the Phe/Asp-IncA1–141 mutant.
To test this possibility, we purified peptides corresponding to the
SNARE-like domain(s) of wildtype IncA, IncA1–141, Phe/Asp-
IncA1–141, and Phe/Asp-IncA and secondary structure was
analyzed using circular dichroism (CD) spectroscopy. These
constructs lack the transmembrane domain and the N-terminal
tail region and are denoted as ‘‘DTMD.’’ DTMD-IncA and
DTMD-IncA1–141 show marked a-helical content as evidenced by
the double minima around 208 nm and 222 nm (Fig. 3D).
Interestingly, DTMD-Phe/Asp-IncA1–141 shows no signs of
secondary structure, indicating that these mutations abolish a-
helicity in this region (Fig. 3E). The lack of secondary structure is
not due to aggregation of the peptide because the protein elutes far
from the void volume on a size exclusion column (Fig. 3E, inset).
Interestingly, the CD spectra of DTMD-Phe/Asp-IncA reveals
strong a-helical content, suggesting SLD2 may fold independently
of SLD1 (Fig. 3F). Together, these data suggest that IncA contains
two CCDs that inhibit SNARE-mediated fusion independently of
one another. The loss of a-helicity correlates with a loss of
inhibitory capacity, however additional experiments will be
necessary to address a possible link between a-helicity and
inhibitory activity. These observations are consistent with IncA
being an inhibitory SNARE-like protein and establish for the first
time the inhibitory role of SLD2.
Both SNARE-like Domains are Required to Induce
Homotypic Fusion of the Inclusions in Host Cells
In addition to inhibiting fusion, IncA is involved in the
homotypic fusion of the inclusions via oligomerization [3] The
process of homotypic fusion is a critical step in the pathogenicity of
C. trachomatis. Failure of the inclusions to fuse results in decreased
bacterial loads and, in infected individuals, subclinical disease
outcomes [4,32]. IncA is a key player in this event because
microinjection of blocking antibodies to IncA or inhibition of type
III secretion results in the formation of nonfusogenic C. trachomatis
inclusions [32–34]. The domains of IncA that play significant roles
in this process are not known. Next, we determined whether the
SNARE-like domains of IncA also play a role in homotypic fusion.
We first performed co-elution experiments to identify the
domains that contribute to the multimerization of IncA. GST-
tagged TfR-IncA was co-expressed with 6xHis-tagged IncA
mutants in BL21(DE3) E. coli. Using the TfR-IncA chimera
allowed us to determine the contribution of the IncA TMD to
multimerization. GST-tagged complexes in the BL21(DE3) lysate
were affinity purified using glutathione agarose beads, and the
resulting complexes were analyzed by SDS-PAGE (Fig. 4A, co-
elution blot). As a control, a plasmid expressing only GST was co-
transformed with the plasmid expressing 6xHis-tagged wildtype
IncA (Fig. 4A, right columns). A striking pattern emerged in our
co-elution experiments in that only those 6xHis-tagged IncA
mutants that contained SLD2 co-purify with GST-TfR-IncA
(Fig. 4A). Wildtype, D34-IncA, and Phe/Asp-IncA all co-purify
while IncA1–141 whereas Phe/Asp-IncA1–141 does not. The N-
terminal tail region and the native transmembrane domain of
IncA are seemingly both dispensable for oligomerization as D34-
IncA (which lacks the N-terminal tail region) co-purifies with
GST-TfR-IncA (lacking both the N-terminal tail region and the
TMD). The lack of binding for both IncA1–141 and Phe/Asp-
IncA1–141 is not due to their low expression level as shown in the
loading control (Fig. 4A, lysate blot).
Transfection of HeLa cells with wildtype IncA leads to growth
defects of developing inclusions due to the interaction of transgenic
IncA with endogenous IncA on the inclusion [35–37]. The
mechanism for this phenotype has yet to be elucidated, but is
believed to be the result of inhibition of homotypic fusion between
two or more inclusions in the same cell [3,34,36]. Therefore, IncA
mutants that do not bind endogenous IncA (i.e. that do not
contain SLD2) should not lead to developmental defects. To test
this hypothesis, we transgenically expressed wildtype IncA, D34-
IncA, IncA1–141, Phe/Asp-IncA1–141, and Phe/Asp-IncA fused to
the monomeric form of DsRed in HeLa cells 24 h prior to
infection with C. trachomatis strain L2 and monitored changes in
inclusion morphology associated with each mutant. For this
experiment, we considered only those cells that were transfected
(DsRed-positive). We found that the overall frequency of infection
(ratio of infected cells to total cells) did not vary significantly (data
not shown). However, we observed marked differences in inclusion
morphology between empty-vector control and DsRed-IncA-
expressing HeLa cells (Fig. 4B). DsRed staining in control cells
was diffuse and single large inclusions are highly visible (Fig. 4B,
first row). Transfection with DsRed-IncA (Fig. 4B, second row)
leads to the formation of multiple inclusions that are reminiscent of
nonfusogenic inclusions described previously (p = 0.001, Fig. 4C)
[3,33,34]. Interestingly, transfection with DsRed-D34-IncA also
leads to non-fusogenic inclusions (Fig. 4B, third row and Fig. 4C
p= 0.008), suggesting that D34-IncA is functional and that the N-
terminal tail does not play a role in homotypic fusion. As expected
from our co-elution data, DsRed-IncA1–141 and DsRed-Phe/Asp-
and Vti1b were reconstituted. Fusion rates were calculated as described in the legend of Figure 2B. Protein gel lanes show co-reconstitution of
VAMP8 and IncA1–141. (B) Phenylalanine and Aspartic acid mutations inactivate SLD1. Increasing concentrations of Phe/Asp-IncA1–141 were
reconstituted in v-SNARE liposomes with VAMP8. v-SNARE liposomes were mixed with t-SNARE liposomes and data analyzed as in (A). (C) SLD2
independently inhibits SNARE-mediated membrane fusion. Increasing concentrations of Phe/Asp-IncA were reconstituted in v-SNARE liposomes with
VAMP8 and v-SNARE liposomes were mixed with t-SNARE liposomes. Data were analyzed as in (A). In A, B, and C, black circles represent fusion in the
absence of IncA and gray squares represent fusion using liposomes containing IncA construct. Results are representative of at least four independent
experiments. (D, E, F) Far-UV CD wavelength scans of IncA constructs. Protein was dissolved in CD Buffer (200 mM NaF, 20 mM Tris, 10% glycerol,
1 mM DTT, pH7.4) to a final concentration of 10 mM and far-UV scans were taken in a 1 mm pathlength quartz cuvette (Starna) at 20uC. Data are the
averages of five scans. For comparison, the CD signal of DTMD-IncA (which contains wildtype SLD1 and SLD2) is shown as a dashed curve. (D) SLD1
displays an a-helical structure. DTMD-IncA1–141 was dissolved in CD Buffer and analyzed as above. (E) Phenylalanine and Aspartic acid mutations
interfere with the a-helical structure of SLD1. DTMD-Phe/Asp-IncA1–141 was dissolved in CD Buffer and analyzed as in (D). The loss of structure cannot
be attributed to aggregation of the protein. Inset shows elution profile of protein (red line) superimposed on elution profile of blue dextran (blue
line) to determine void volume. The protein elutes far from the blue dextran indicating a soluble species of protein. (F) Phe/Asp-IncA displays an a-
helical structure. DTMD-Phe/Asp-IncA was dissolved in CD Buffer and analyzed as in (D).
doi:10.1371/journal.pone.0069769.g003
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IncA1–141 do not have any effect on inclusion development
compared with vector control (Fig. 4B, fourth and fifth rows,
respectively and Fig. 4C). Surprisingly, transfection with DsRed-
Phe/Asp-IncA, which contains SLD2 (but in which SLD1 is
inactivated), fails to inhibit inclusion development (Fig. 4C,
p=0.072). Inclusions appeared normal as in the vector control,
suggesting that Phe/Asp-IncA lost its activity in homotypic fusion
(Fig. 4B, sixth row). We conclude that, although SLD2 is necessary
and sufficient for oligomerization in vitro, under physiologic
Figure 4. SLD2 is required for oligomerization but both SNARE-like domains are necessary for homotypic fusion. (A) SLD2-containing
IncA mutants co-elute with GST-TfR-IncA. 6xHis-tagged IncA mutants were co-expressed with GST-TfR-IncA in BL21(DE3) E. coli, and GST-containing
complexes were purified over glutathione beads. Co-eluted IncA mutants were detected by western blot using anti-6xHis antibody. GST-TfR-IncA was
visualized by Coomassie Blue staining. IncA mutants that contain SLD2 co-precipitated while the two truncated mutants lacking SLD2 did not. GST
control shows basal levels of wildtype 6x-His-IncA binding. Results shown are typical of five independent experiments. (B) Transfection with wildtype-
or D34-IncA leads to nonfusogenic inclusions. HeLa cells were transfected with plasmids expressing the indicated DsRed-IncA mutant or vector
control (pDsRed-monomer-C1) and subsequently infected with C. trachomatis L2 for 24 hr. The location of each DsRed-IncA construct is shown on
the left (red), while the inclusions are shown in the middle (blue, Hoechst staining). The right column shows the overlay. Arrows denote inclusions.
Note the multiple inclusions in wildtype-IncA and D34-IncA transfected cells compared to the cells transfected with other IncA constructs. Scale bars
represent 10 mm. Images are typical of four independent experiments. (C) Expression of either wildtype or D34-IncA inhibits subsequent inclusion
development in HeLa cells. The number of inclusions/cell was determined by fluorescence microscopy. More than fifty infected cells per replicate per
transfection were assessed for multiple inclusions. The number of infected cells carrying a single inclusion was divided by the total number of
infected cells and expressed as a percent. Data are averages of four independent experiments. Error bars represent one standard deviation. Asterisks
denote a significant difference compared to control-transfected cells (p,0.05).
doi:10.1371/journal.pone.0069769.g004
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conditions, it requires SLD1 to be fully functional and promote
homotypic fusion of inclusions.
Discussion
Chlamydia trachomatis is one of the most skilled pathogens in co-
opting host fusion, able to inhibit host pathways while inducing
new fusion events. The Chlamydia SNARE-like protein IncA
appears to play a major role in both of these processes. During
infection, IncA is involved in both the inhibition of host endocytic
SNARE-mediated membrane fusion [20] and in the induction of
inclusion homotypic fusion [3,33]. How IncA establishes a delicate
balance between blocking endosomal/lysosomal membrane fusion
events and activating new fusion events between inclusions is
unknown, and, despite its importance in manipulating membrane
fusion, a detailed mechanism of IncA function remains unknown.
In the present study, we first established that IncA must be located
on the same membrane than the target SNAREs to exert its
inhibitory function (Fig. 1). This result is consistent with the
restricted disturbance of membrane fusion by the inclusion, which
leaves other vesicle trafficking events intact. In fact, Chlamydia does
not affect vesicular trafficking in the rest of the cell as the general
endocytic pathway in infected cells remains functional [11].
IncA is organized in distinctive domains (see Fig. 2A). The N-
terminal region of the protein encompasses a tail region (residues
1–34) and a bilobed transmembrane domain (TMD), for which no
specific function is known. The tail region reveals no obvious
signature of a-helices or b-sheets based on secondary structure
prediction algorithms, yet it is facing the host cytosol where it has
the potential to interact with host proteins and manipulate
membrane fusion [21]. The transmembrane domain (TMD) has
unique characteristics. At ,40 amino acids, it is about twice as
long as that of a typical single pass transmembrane protein, and
has been termed ‘‘bi-lobed’’ [38]. For comparison, the SNARE
proteins used in this study Stx7, Stx8, Vti1b, and VAMP8 each
have TMDs of between 20 and 23 residues. In the present study,
domain swap/deletion experiments conclusively show that both
these domains are dispensable for IncA to inhibit SNARE
complexes since their removal did not abrogate its function
(Fig. 2C). Furthermore, the deletion of the N-terminal tail does not
prevent IncA from multimerizing (Fig. 4A), and transgenic
expression of D34-IncA inhibited subsequent inclusion develop-
ment. Altogether, these results demonstrate that the N-terminal
domain containing the N-terminal tail and the transmembrane
domain are not functionally involved in membrane fusion.
However, it has been previously shown that the N-terminal
domain functions in the targeting of the protein to the inclusion
membrane through the type 3 secretory system [39]. Thus, it
seems that the function of the N-terminus of IncA is restricted to
protein translocation to the inclusion surface.
As for the cytosolic C-terminal domain of IncA, it contains two
SNARE-like domains, SLD1 and SLD2. Previously, we have
shown that the N-terminal SNARE-like domain SLD1 is sufficient
to inhibit endocytic SNARE-mediated membrane fusion [20]. The
molecular dissection of IncA presented in this study now reveals a
role for the C-terminal SNARE-like domain SLD2. By targeting
key residues important for a-helicity and coiled-coil integrity in
SLD1, we first inactivated this domain, thus only leaving SLD2
active (Fig. 3). Using an in vitro fusion assay, we then observed that
SLD2 independently contributes to the inhibition of SNARE-
mediated membrane fusion. Intriguingly, the loss of inhibitory
function of SLD1 correlates with the loss of secondary structure as
observed by far-UV circular dichroism analysis. Although more
experiments will be required to functionally validate this observa-
tion, it is consistent with the hypothesis that SNARE-like domains
require a-helical structure in order to be active.
We can speculate on a functional mechanism for each IncA
SLD based on studies of the eukaryotic membrane fusion system.
One possibility is that IncA binds the SNAREs and functions like
inhibitory SNAREs, or i-SNAREs. i-SNAREs fine-tune SNARE-
mediated fusion by inhibiting constitutive SNARE complex
formation and membrane fusion [40]. Varlamov et al. showed
that the yeast Golgi SNARE complex composed of Sed5, Sec22,
Bos1, and Bet1, is inhibited by the presence of non-cognate
SNAREs Gos1, Tlg1 and Sft1 on the liposome [40]. Moreover,
this effect is dose-dependent because adding more Bos1 to the t-
SNARE liposome suppressed the inhibitory phenotype suggesting
that the i-SNAREs were forming nonfusogenic pseudo-SNARE
complexes [40]. IncA could also form nonfusogenic pseudo-
SNAREs by competing with one or all of the t-SNAREs (Stx7,
Stx8, Vti1b) to bind to VAMP8. Computational modeling and
in vitro pulldown data support this scenario [22]. Subtil and co-
workers showed that a tetrameric complex consisting of three
SLD2 domains and one VAMP8 molecule would likely be
structurally similar to a bona-fide SNARE four-helix bundle
[22]. Alternatively, the formation of non-functional SNARE
complexes is known to occur in other biological contexts and
IncA could function in a different way. The proteins of the
complexin family, for example, insert themselves in an antiparallel
orientation into SNARE complexes and create alternative coiled-
coils that effectively arrest SNAREs in a non-fusogenic state [41–
43]. It is tempting to speculate that alternative coiled-coil
formation evolved as an efficient strategy to block membrane
fusion and control vesicle traffic and that intracellular pathogens
may have acquired similar systems to thwart host defenses.
Structural studies will be required to discriminate between both of
these possibilities.
The previously noted correlation between inca expression and
homotypic fusion, combined with the presence of coiled-coil
domains resembling SNARE motifs, led us to hypothesize a role
for these domains in activating fusion. To test this hypothesis, we
first assessed the IncA mutants for their ability to oligomerize,
since IncA oligomerization appears to be part of the fusion process
[3]. Using a co-elution strategy, we found that only those IncA
mutants containing SLD2 co-eluted with GST-TfR-IncA that
encodes an intact C-terminal cytoplasmic domain (Fig. 4A).
Surprisingly, we found that both SLDs are required to efficiently
interfere with homotypic fusion in a cellular assay, suggesting that
both domains are involved in the formation of a fusogenic coiled-
coil bundle [22]. These results are consistent with previous yeast
two-hybrid and microscopy assays, which determined that the C-
terminal cytoplasmic domain is necessary to promote IncA
oligomerization and fusion of multiple inclusions in the same cell
[3]. Similar to the fusogenic SNARE four-helix bundle [44,45],
our results suggest that IncA may require both SLDs in order to
promote homotypic fusion.
While IncA is required for homotypic fusion, it is likely not
sufficient for fusion because species that do not fuse inclusions such
as Chlamydophila psittaci, contain homologous inca genes [46]. It
should also be noted that amino acid sequence conservation
between Inc proteins of different species is relatively low [38].
Therefore, sequence orthology may not imply functional homol-
ogy, and the non-fusogenic phenotype could be due to genetic
variation in inca. More experiments are needed to determine the
exact mechanism of inclusion fusion.
Altogether, these results imply that the function of each SLD
may be context dependent. Either domain is capable of inhibiting
late endosome/lysosome fusion to shield the inclusion from
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degradation (Fig. 3), but both domains appear to be required to
promote homotypic interaction between inclusions (Fig. 4). It is
conceivable that C. trachomatis evolved redundant CCDs capable of
inhibiting SNARE fusion as a way to protect itself from deleterious
mutations to one or both domains over time. The ability of IncA to
promote homotypic interaction between C. trachomatis inclusions
could have arisen later in evolutionary time partly as a
consequence of the two CCDs. Additional molecular components
are likely to be involved in the homotypic fusion process since all
Chlamydia IncA homologues present two CCDs, yet, only IncA
expressed by C. trachomatis is implicated in homotypic fusion [3].
Future Directions
If SNARE-like proteins are such an important and efficient
system to corrupt host SNAREs and manipulate membrane
fusion, could they be used by other intracellular bacteria? The
intracellular bacterial pathogen Mycobacterium tuberculosis was
responsible for 1.4 million deaths in 2011 (World Health
Organization). Like Chlamydia, one key aspect of the pathogenicity
of mycobacteria is interference with lysosomal fusion. Although
some strategies that mycobacteria use to block phagosomal
maturation are known, their impact on the SNARE fusion
machinery is understudied. Do they use inhibitory SNARE-like
proteins and co-opt host SNAREs to establish and protect their
infectious compartment? The same question applies to many more
intracellular bacteria, including Salmonella typhi, Brucella abortus,
Legionella pneumophila, all significant health and economic burdens.
Ultimately, the discovery that a variety of intracellular bacteria
utilize SNARE-like proteins to protect their infectious compart-
ment implies evolutionary conservation, and could lead to a major
therapeutic effort in this direction.
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